Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 138   

Articles published

NVS 90.15 +0.91 (1.02%)
price chart
Stocks in Focus- Bristol-Myers Squibb Co (NYSE:BMY), Novartis AG (ADR ...
Novartis AG (ADR) (NYSE:NVS) declared that the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee has mutually voted in favor of admiring AIN457 a selective interleukin-17A inhibitor for the treatment of moderate to severe plaque psoriasis in ...
Related articles »  
Stocks Alert: Novartis AG (ADR) (NYSE:NVS), Chimerix Inc (NASDAQ:CMRX ...
Novartis AG (ADR) (NYSE:NVS) said three members of its executive committee will leave the health-care company following the completion of the sales of its animal health, OTC drugs, and vaccine units to Eli Lilly (LLY) and GlaxoSmithKline (GSK).
Related articles »  
Novartis Announces Positive Phase-III Results For Secukinumab
Novartis AG (ADR) (NVS) announced today that its experimental drug AIN457 (Secukinumab) met its primary and secondary end points in two late-stage trials called MEASURE 1 and MEASURE-2.
Related articles »  
FDA Advisory Committee Votes In Favor Of Novartis' IL-17 Inhibitor
Novartis AG (ADR) (NVS) announced yesterday that the Dermatologic and Ophthalmic Drugs Advisory Committee to the FDA has unanimously recommended the use of Novartis' AIN457 in adults who are suffering from moderate-to-severe plaque psoriasis.
Related articles »  
Volatile Movements - Novartis AG (ADR) (NYSE:NVS), Garmin Ltd. (NASDAQ ...
Novartis AG (ADR) (NYSE:NVS) offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical ...
Eye Catching Stocks: EXCO Resources Inc (NYSE:XCO), Novartis AG (ADR ...
Novartis AG (ADR) (NYSE:NVS) presents data at EADV showing reliable efficiency of AIN457 in clearing skin of psoriasis patients (NVS) : new investigation of AIN457 (secukinumab) Phase III studies explains that treatment with secukinumab 300 mg resulted ...
Related articles »  
Novartis's Signifor Closer To EU Approval
Novartis's Signifor is capable of treating acromegaly in adults, who are unable to go through a surgery as an alternative option, and those on whom first-generation somatostatin analogues (SSAs), including Novartis's Sandostatin LAR, have not worked ...
Novartis Releases Positive Phase 3 Results For Psoriatic Arthritis Drug
Novartis AG (ADR) (NVS) today released top line results for two late-stage pivotal studies, which evaluated its novel drug secukinumab as a treatment for psoriatic arthritis (PsA).
Related articles »  
Sizzling news - Novartis AG (ADR) (NYSE:NVS), Royal Dutch Shell plc (NYSE ...
Manhattan, NY- September 30, 2014 - (Techsonian) - Novartis AG (ADR) (NYSE:NVS)offers patented prescription medicines in a variety of therapeutic areas, including oncology; most important care and established medicines; specialty care, such as ...
Related articles »  
Pharma Stock Updates - Pfizer Inc. (NYSE:PFE), Novartis AG (ADR) (NYSE:NVS ...
Novartis AG (ADR) (NYSE:NVS) said late on Wednesday that its experimental drug secukinumab worker better than a placebo in two pivotal Phase III studies on psoriatic arthritis, a long-lasting condition that causes joint pain and stiffness and which ...
Related articles »